FIND-CKD was a 56-week , open-label , multicentre , prospective , randomized three-arm study ( NCT00994318 ) of 626 patients with ND-CKD and iron deficiency anaemia randomized to ( i ) intravenous ( IV ) ferric carboxymaltose ( FCM ) at an initial dose of 1000 mg iron with subsequent dosing as necessary to target a serum ferritin level of 400-600 g/L ( ii ) IV FCM at an initial dose of 200 mg with subsequent dosing as necessary to target serum ferritin 100-200 g/L or ( iii ) oral ferrous sulphate 200 mg iron/day .
